ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
122.331,39
0,00%
S&P 500
5.469,30
0,00%
US Dollar vs BRL
5,5048
0,96%
Bitcoin
61.394,30
-0,67%
Brent Oil
84,235
0,06%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Virios Therapeutics Inc (VIRI)

  7. Virios Therapeutics Inc (VIRI) Notícias

VIRI

Virios Therapeutics (VIRI)

Virios Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:VIRI
DataHoraFonteTítuloCódigoCompanhia
20/06/202410:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRIVirios Therapeutics Inc
22/05/202414:30GlobeNewswire Inc.Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b StudyNASDAQ:VIRIVirios Therapeutics Inc
20/05/202417:05Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:VIRIVirios Therapeutics Inc
19/05/202421:53GlobeNewswire Inc.Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b StudyNASDAQ:VIRIVirios Therapeutics Inc
17/05/202417:10GlobeNewswire Inc.Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b StudyNASDAQ:VIRIVirios Therapeutics Inc
10/05/202411:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VIRIVirios Therapeutics Inc
09/05/202408:45GlobeNewswire Inc.Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:VIRIVirios Therapeutics Inc
02/05/202410:15GlobeNewswire Inc.Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024NASDAQ:VIRIVirios Therapeutics Inc
26/03/202410:15GlobeNewswire Inc.Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVIDNASDAQ:VIRIVirios Therapeutics Inc
08/03/202419:00Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:VIRIVirios Therapeutics Inc
01/03/202411:10Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:VIRIVirios Therapeutics Inc
29/02/202411:15GlobeNewswire Inc.Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:VIRIVirios Therapeutics Inc
28/02/202415:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRIVirios Therapeutics Inc
28/02/202411:15GlobeNewswire Inc.Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming MilestonesNASDAQ:VIRIVirios Therapeutics Inc
02/02/202418:31Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:VIRIVirios Therapeutics Inc
22/01/202411:33Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:VIRIVirios Therapeutics Inc
22/01/202411:00GlobeNewswire Inc.Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVIDNASDAQ:VIRIVirios Therapeutics Inc
02/01/202409:05GlobeNewswire Inc.Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVIDNASDAQ:VIRIVirios Therapeutics Inc
13/11/202309:05GlobeNewswire Inc.Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:VIRIVirios Therapeutics Inc
06/11/202309:05GlobeNewswire Inc.Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023NASDAQ:VIRIVirios Therapeutics Inc
12/10/202308:05GlobeNewswire Inc.Virios Therapeutics to Present at the ThinkEquity Conference on Thursday, October 19, 2023NASDAQ:VIRIVirios Therapeutics Inc
18/09/202308:05GlobeNewswire Inc.Virios Therapeutics Announces Termination of At-The-Market Sales AgreementNASDAQ:VIRIVirios Therapeutics Inc
12/09/202308:05GlobeNewswire Inc.Virios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023NASDAQ:VIRIVirios Therapeutics Inc
14/08/202308:05GlobeNewswire Inc.Virios Therapeutics Announces Halt to At-The-Market Offering SalesNASDAQ:VIRIVirios Therapeutics Inc
10/08/202308:05GlobeNewswire Inc.Virios Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:VIRIVirios Therapeutics Inc
09/08/202308:05GlobeNewswire Inc.Virios Therapeutics Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as a New Treatment Option for FibromyalgiaNASDAQ:VIRIVirios Therapeutics Inc
03/08/202317:05GlobeNewswire Inc.Virios Therapeutics to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023NASDAQ:VIRIVirios Therapeutics Inc
17/07/202308:05GlobeNewswire Inc.Virios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-COVID Symptoms Following Treatment with a Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept StudyNASDAQ:VIRIVirios Therapeutics Inc
14/07/202317:12Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:VIRIVirios Therapeutics Inc
20/06/202315:07Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VIRIVirios Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:VIRI

Seu Histórico Recente

USOTC
LLGCF
Lendlease Global Commerc... (PK)
BIBX
LITETH
Lition
USOTC
NKUEF
Nittoku (GM)
BIT
GS0120
Goldman Sachs
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados